Hong Jun Liang
Director/Board Member at BEIJING STRONG BIOTECHNOLOGIES,INC.
Profile
Hong Jun Liang is currently the Vice Chairman at Beijing Strong Biotechnologies, Inc. and Director at Fuzhou Maixin Biotech Co., Ltd.
Previously, he served as the Chairman-Supervisory Board at Shanghai Shyndec Pharmaceutical Co., Ltd.
and as a Director at Jiangsu Hengrui Pharmaceuticals Co., Ltd.
from 2018 to 2020.
Hong Jun Liang active positions
Companies | Position | Start |
---|---|---|
BEIJING STRONG BIOTECHNOLOGIES,INC. | Director/Board Member | 12/08/2020 |
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Director/Board Member | 14/09/2020 |
Former positions of Hong Jun Liang
Companies | Position | End |
---|---|---|
JIANGSU HENGRUI MEDICINE CO., LTD. | Director/Board Member | 31/12/2019 |
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. | Chairman | 14/11/2019 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
JIANGSU HENGRUI MEDICINE CO., LTD. | Health Technology |
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. | Health Technology |
BEIJING STRONG BIOTECHNOLOGIES,INC. | Health Technology |
Private companies | 1 |
---|---|
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Health Services |
- Stock Market
- Insiders
- Hong Jun Liang